S. Yin

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

R. Stocco, A. Roulston, Jordan T. F. Young, 2021, Molecular Cancer Therapeutics.

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.

R. Stocco, F. Sicheri, P. Beaulieu, 2022, Journal of medicinal chemistry.